BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer

Advances in PARP inhibitor use for metastatic breast cancer

Margetuximab for the treatment of HER2-positive breast cancer

DORA: Using olaparib alone or with durvalumab in platinum responsive advanced triple-negative breast cancer

EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer

Guiding treatment decisions through the use of molecular profiling in breast cancer

Managing metastatic breast cancer and beyond using PARP inhibitors

Updates in metastatic and early-stage breast cancer

PARP inhibitors in metastatic breast cancer: Where are we now?

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer